Last reviewed · How we verify

NCT07082933

Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes

Not yet recruiting Last updated 24 July 2025
What this trial tests

trial testing Standard medical treatment in Pulmonary Arterial Hypertension (PAH) in 5,000 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
1 August 2027
31 December 2027

Quick facts

Lead sponsorXijing Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment5,000
Start date1 August 2025
Primary completion1 August 2027
Estimated completion31 December 2027

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

Adults 18 to 80, any sex, with Pulmonary Arterial Hypertension (PAH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes, and analysis the risk factors of the overall survival .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard medical treatment

Trials testing the same drug.

Other recruiting trials for Pulmonary Arterial Hypertension (PAH)

Currently open trials in the same condition.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07082933.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing